Table 1_Case Report: Treatment of refractory lung disease in systemic juvenile idiopathic

Two pediatric case reports detail the treatment of refractory systemic juvenile idiopathic arthritis-associated lung disease (sJIA-LD) with cyclophosphamide and rituximab combination therapy. The report, authored by William J. Freeman and published on figshare under CC-BY-4.0, was last updated on 2026-05-04. It documents clinical improvements including reduced oxygen requirements and improved pulmonary hypertension measures.

Use Cases

• Analyzing treatment outcomes for refractory sJIA-LD based on detailed clinical metrics like pulmonary arterial pressure and oxygen requirement.
• Studying the efficacy of cyclophosphamide and rituximab combination therapy based on case-specific results such as ferritin levels and CT scan improvements.
• Investigating correlations between lung disease, pulmonary hypertension, and macrophage activation syndrome in sJIA based on the described patient histories.

Strengths

• Provides specific, quantified clinical outcomes, such as a reduction in mean pulmonary arterial pressure from 47 to 25 mmHg.
• Includes detailed longitudinal patient data on multiple measures like prednisone dosage, height velocity, and CT scan findings.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is a 15.5 KB document, indicating a very limited scope of two case reports.

Provenance

Source

figshare

Collection Method

Clinical case report documentation.

Time Range

Time range of the reported cases is not specified.

Freshness

Last updated 2026-05-04 04:24:24; freshness should be verified.

Geography

Geographic coverage is not specified.